Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - GI, colorectal

397O - Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study

Date

19 Sep 2020

Session

Proffered Paper - GI, colorectal

Presenters

Erika Martinelli

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

E. Martinelli1, G. Martini2, T. Troiani1, F. Pietrantonio3, A. Avallone4, N. Normanno5, A. Nappi6, E. Maiello7, A. Falcone8, G. Santabarbara9, C. Pinto10, D. Santini11, D. Ciardiello2, M. Terminiello12, C. Borrelli1, S. Napolitano2, D. Renato1, V. Famiglietti1, L. Esposito1, F. Ciardiello2

Author affiliations

  • 1 Department Of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 2 Department Of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 3 Istituto Tumori Milano, Medical Oncoloy, 20133 - Milano/IT
  • 4 Medical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 5 Translational Research Dept., Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 6 Medical Oncoloy, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 7 Medical Oncoloy, IRCCS Fondazione Casa Sollievo della Sofferenza, 71013 - San Giovanni Rotondo/IT
  • 8 Oncology Dept., Azienda Ospedaliero Universitaria Pisana - Stabilimento di Santa Chiara, 56100 - Pisa/IT
  • 9 Medical Oncology, Azienda Ospedaliera di Rilievo Nazionale “S. G. Moscati”,, 83100 - Avellino/IT
  • 10 Medical Oncology, IRCCS Santa Maria Nuova, Reggio Emilia, 42121 - Reggio Emilia/IT
  • 11 Oncology Dept., Policlinico Universitario Campus Bio-Medico, 128 - Rome/IT
  • 12 Dipartimento Medicina Di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
More

Resources

Login to access the resources on OncologyPRO.

Abstract 397O

Background

Rechallenge strategies with anti-epidermal growth factor receptor (EGFR) drugs have been evaluated in patients (pts) with refractory RAS/BRAF wild type (WT) mCRC after response to anti-EGFR based 1st line therapy. Given the role of cetuximab in enhancing antibody-dependent cellular cytotoxicity (ADCC) and promoting expression of MHC class II molecules on dendritic cells, its association with anti-PD-L1 avelumab may be a relevant rechallenge strategy in RAS WT mCRC.

Methods

CAVE mCRC, a single arm multi-centre phase II study, aims to evaluate the efficacy of avelumab and cetuximab in RAS WT mCRC pts treated in first line with chemotherapy (CT) in combination with anti-EGFR drugs and who achieved a complete (CR) or partial response (PR). Primary endpoint is median overall survival (mOS), secondary endpoints are overall response rate (ORR) according to RECIST 1.1, progression free survival (PFS) and safety profile. This study seeks to demonstrate a mOS of 11 months (mo) for the experimental combination in comparison with historical mOS of 8.0 mo with standard third line treatments, which corresponds to an improvement in mOS of 37,5 %.

Results

From August 10, 2018 to February 21, 2020, 77 pts have been enrolled and started treatment with avelumab 10 mg/kg q14 and cetuximab at 400 mg/m2 and subsequently 250 mg/m2 weekly until progression of disease (PD) or unacceptable toxicity. Kaplan-Meier curves estimated for the whole intention-to-treat (ITT) population (77 pts): mOS was 13.1 mo (95% Confidence Interval CI, 7.4-18.8 mo; 32 events); mPFS, 3.6 mo (95% CI, 3.3-3.9 mo; 62 events). Among 65 pts evaluable for response, 1 pt (1.5%) experienced CR, 3 pts (4.6%) PR, 32 pts stable disease (SD) (49.2%); 29 pts PD (44.6%). Pts with PFS≥ 6 mo were 12/65 (18.5%). Grade-3 adverse events were reported in 16/77 pts (22%), the most common being skin rash 10/77 (13%) and diarrhoea 3/77 (4%).

Conclusions

At this preliminary analysis, avelumab plus cetuximab as a rechallenge strategy is effective and well tolerated in chemorefractory RAS/BRAF WT mCRC pts. The final analysis for OS will be presented at the ESMO 2020 congress.

Clinical trial identification

EudraCT 2017-004392-32.

Editorial acknowledgement

Legal entity responsible for the study

Department of Precision Medicine, Università degli Studi della Campania \"L. Vanvitelli\".

Funding

Merck.

Disclosure

E. Martinelli: Advisory/Consultancy: Amgen, Bayer, Merck-Serono, Roche, Sanofi, Servier, Pierre Fabre. T. Troiani: Advisory/Consultancy: Roche, Merck, Sanofi, Servier, Novartis, Bayer. F. Pietrantonio: Advisory/Consultancy: Amgen, Roche, Lilly, Sanofi, Merck-Serono, Bayer, Servier; Research grant/Funding (self): BMS. A. Avallone: Advisory/Consultancy: Amgen ; Speaker Bureau/Expert testimony: Servier . N. Normanno: Advisory/Consultancy: MSD, Qiagen, Biocartis, Incyte, Roche, BMS, MERCK, Thermofisher,Boehringer Ingelheim, Astrazeneca, Sanofi, Eli Lilly, Bayer. E. Maiello: Advisory/Consultancy: Astra Zeneca, Eli Lilly, Servier, Sanofi Genzyme, Roche, Merck, Eisai, Pfizer. A. Falcone: Advisory/Consultancy: Bayer, Bristol, Eli Lilly, Merck, Pierre-Fabre, Roche, Servier, and institutional support for clinical trials from Astra-Zeneca, Bayer, Bristol, Eli Lilly, Merck, MSD, Novartis, Roche, Sanofi, and Servier. C. Pinto: Advisory/Consultancy, Speaker Bureau/Expert testimony: BMS, MSD, Bayer, Astra-Zeneca, Roche, Merck, Lilly, Servier, Sanofi, Astellas. F. Ciardiello: Advisory/Consultancy: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Cellgene, Lilly; Research grant/Funding (self): Bayer, Roche, Merck, Amgen, AstraZeneca, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings